Patent intelligence · US
US 8183361
Oligonucleotide-containing pharmacological compositions and their use
Oligonucleotide-containing pharmacological compositions and their use
Patent details — US 8183361
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 22, 2012
- Expiration
- May 17, 2032
- Applicant
- Lakewood Amedex, Inc.
- Claims
- 12
- CPC classes
- A61K, A61K2800/74, A61K38/00, A61K8/606
Quick answer
US 8183361 (Oligonucleotide-containing pharmacological compositions and their use) is held by Lakewood Amedex, Inc.. Status: granted. Granted May 22, 2012. Expires May 17, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lakewood Amedex, Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K2800/74, A61K38/00, A61K8/606, A61P, A61P1/00
More from Lakewood Amedex, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12156883
Bisphosphocin gel formulations and uses thereof
granted -
US 12054509
Antimicrobial compounds, compositions, and uses thereof
granted -
US 12030908
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11795192
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11377468
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11123357
Methods and compositions for treating oral mucositis
granted -
US 11096954
Bisphosphocin gel formulations and uses thereof
granted -
US 10981943
Antimicrobial compounds, compositions, and uses thereof
granted
Frequently asked questions
What is US patent 8183361?
US 8183361 (Oligonucleotide-containing pharmacological compositions and their use) is held by Lakewood Amedex, Inc.. Status: granted. Granted May 22, 2012. Expires May 17, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8183361?
Lakewood Amedex, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 18 pharmaceutical patents for this assignee.
When does US 8183361 expire?
Our index shows an expiration date of May 17, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.